Tiziana’s Phase IIa trial of foralumab meets dual endpoints in na-SPMS
Tiziana Life Sciences has reported that its Phase IIa INFORM-MS study of intranasal foralumab for non-active secondary progressive multiple sclerosis…
Tiziana Life Sciences has reported that its Phase IIa INFORM-MS study of intranasal foralumab for non-active secondary progressive multiple sclerosis…
Teva Pharmaceuticals has announced plans to halt a Phase II clinical trial evaluating emrusolmin (TEV-'286) to treat adults with multiple…
Pretzel Therapeutics has received authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with a clinical…
Shanghai Zhimeng Biopharma has completed patient enrolment in the pivotal Phase II/III clinical trial of its investigational potassium-channel opener, CB03-154,…
Taiho Oncology chief medical officer (CMO) Dr Harold Keer recently discussed with Srivani Venna the outcomes from the Phase III REZILIENT3…
Akeso has commenced a global Phase III clinical trial, with the enrolment of the first patient, to evaluate its bispecific antibody,…
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to…
Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with…
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
PepGen has announced that an independent Data and Safety Monitoring Board (DSMB) has approved the progression to the highest dosage…